Ad
Sunday, 1 July 2018
Roche 'highly encouraged' by Tecentriq results in breast cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment